Table 1.

Quick snapshot of PCBCL.

Histological Type	Presentation	Most common involved sites	Behavior	Immunohistochemical	Treatment
PCMZL	Red-violaceous small solitary or multiple papules or nodules and rarely plaques	Trunk, arms or head	Indolent	CD20 +, CD79a +, BCL2 +, CD5-, CD10-, BCL 6-, MUM 1 -	Radiotherapy or surgical excision, topical drugs, intralesional therapies, immunochemotherapy
PCFCL	Solitary or grouped erythematous or erythemato-violaceous papules, plaques, and/or nodules	Trunk, head or neck	Indolent	CD20+, CD79a+, CD5-, CD10+/-, BCL 6+, BCL2-, MUM-1/IRF-4 negative	Radiotherapy or surgical excision, topical drugs, intralesional therapies, immunochemotherapy
PCDLBCL	Erythemato-cyanotic plaques and/or nodules with rapid growth	Legs	Aggressive	CD20+, CD79a+, BCL2+, CD10-, BCL 6+/-, FOX-P1 and MUM-1/IRF-4 positive	Local radiotherapy, R-CHOP, pegylated liposomal doxorubicin, monoclonal antibodies
IVBCL	Violaceous patches and plaque, painful blue-red nodules, ulcerated tumors or telangiectasic skin lesions	SNC, lungs, and skin	Aggressive	CD20 +, BCL 2+, IRF4/MUM-1 + (MIB-1/Ki 67++)	Chemotherapy in combination with rituximab
EBV-MCU	Solitary, sharply demarcated ulcerating lesion	Oropharyngeal mucosa, skin and gastrointestinal tract	Indolent	Variable expression of CD20; CD19+, CD79a +, CD10-, CD30+, BCL2+, PAX 5+, BCL 6 -, MUM-1/IRF-4+	Local radiotherapy or surgical excision, systemic chemotherapy, rituximab